About Mast Therapeutics (NYSE:MSTX)
Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NYSE:MSTX
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $0.12
- 200 Day Moving Avg: $0.11
- 52 Week Range: $0.07 - $0.71
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.76
- P/E Growth: 0.00
- Average Volume: 5.10 million shs.
Frequently Asked Questions for Mast Therapeutics (NYSE:MSTX)
What is Mast Therapeutics' stock symbol?
Mast Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "MSTX."
How were Mast Therapeutics' earnings last quarter?
Mast Therapeutics Inc (NYSE:MSTX) posted its quarterly earnings data on Tuesday, August, 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.01. View Mast Therapeutics' Earnings History.
Who are some of Mast Therapeutics' key competitors?
Some companies that are related to Mast Therapeutics include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), ProMetic Life Sciences (PLI), Theratechnologies (TH), SIGA Technologies (SIGA), Mirati Therapeutics (MRTX), Anavex Life Sciences Corp. (AVXL), Osiris Therapeutics (OSIR), XOMA Corporation (XOMA), VBI Vaccines (VBIV), Protalix Biotherapeutics (PLX), Trillium Therapeutics (TRIL), ContraFect Corporation (CFRX), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Concordia International Corp (CXR), Can Fite Biopharma Ltd (CANF) and Can Fite Biopharma Ltd (CANF).
What is Mast Therapeutics' stock price today?
MarketBeat Community Rating for Mast Therapeutics (NYSE MSTX)MarketBeat's community ratings are surveys of what our community members think about Mast Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Mast Therapeutics stock can currently be purchased for approximately $0.13.
Earnings History for Mast Therapeutics (NYSE:MSTX)Earnings History by Quarter for Mast Therapeutics (NYSE MSTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Mast Therapeutics (NYSE:MSTX)
Current Year EPS Consensus Estimate: $-0.16 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS
Dividend History for Mast Therapeutics (NYSE:MSTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mast Therapeutics (NYSE:MSTX)Insider Trades by Quarter for Mast Therapeutics (NYSE:MSTX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/27/2015||Brandi Roberts||CFO||Buy||38,000||$0.50||$19,000.00|| |
Headline Trends for Mast Therapeutics (NYSE:MSTX)
Latest Headlines for Mast Therapeutics (NYSE:MSTX)
Loading headlines, please wait.
Mast Therapeutics (MSTX) Chart for Tuesday, October, 24, 2017